PSA vs VTGN · rev $4.82B vs rev $176.0K
PSA (PSA) versus VistaGen Therapeutics Inc (VTGN) — a side-by-side from cached financials, not a winner call.
PSA (PSA) common stock.
VistaGen Therapeutics Inc (VTGN) is a biotechnology company listed on NASDAQ.
Latest reported PSA revenue for 2025-12-31 was $4.82B. Net income was $1.78B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. PSA currently screens at market cap $0.
Latest reported VTGN revenue for 2023-03-31 was $176.0K. Net income was -$12.2M. VTGN currently screens at market cap $28.1M.
PSA currently screens at market cap $0. VTGN currently screens at market cap $28.1M.
Not investment advice. Open the PSA and VTGN stock pages for the full models.
Not investment advice.